Albuterol and Ipratropium Oral Inhalation

Albuterol and ipratropium inhalation is a combination bronchodilator (airway opener) approved for use in COPD when a single bronchodilator is not enough.

• Combivent Respimat (inhaler) is indicated for adults with COPD who are already on a regular aerosol bronchodilator but continue to have bronchospasm and need a second bronchodilator.
• Ipratropium Bromide and Albuterol Sulfate Inhalation Solution (nebulizer) is indicated for adults with COPD on a regular aerosol bronchodilator who continue to have bronchospasm and require a second bronchodilator.

This medicine contains two bronchodilators that open the airways through different pathways. Albuterol stimulates beta-2 receptors on the smooth muscle lining the airways, triggering a chain reaction that relaxes the muscle and widens the airway. Ipratropium blocks muscarinic receptors — the docking sites for acetylcholine, a chemical that would otherwise cause airway muscles to contract. Because they work by two separate mechanisms, the combination produces greater airway opening than either drug alone at its recommended dose.

Both products are inhaled — Combivent Respimat through a handheld soft-mist inhaler, and Ipratropium Bromide and Albuterol Sulfate Inhalation Solution through a jet nebulizer connected to an air compressor with a mouthpiece or face mask. These medicines are generally used multiple times per day.

• Always follow your prescriber's exact instructions — do not use more doses or use it more often than directed.
• If a previously effective dose stops working as well, contact your doctor promptly rather than simply taking extra doses.
• There is no food restriction with inhaled medicines, but follow any additional device-care instructions included with your product.

The most common side effects reported with this combination are generally mild and respiratory in nature.

• Upper respiratory infection
• Nasopharyngitis (nose and throat irritation)
• Cough
• Bronchitis
• Headache
• Shortness of breath (dyspnea)

More serious reactions — including paradoxical bronchospasm (sudden airway tightening after a dose), significant heart rate or blood pressure changes, severe allergic reactions, eye pain from accidental spray contact, and difficulty urinating — require prompt medical attention. Stop the medicine and seek help immediately if any of these occur.

• Paradoxical bronchospasm: In rare cases this medicine can cause the airways to tighten instead of open. Stop using it immediately and get medical help if breathing suddenly worsens after a dose.
• Do not exceed the prescribed dose: Fatalities have been reported with overuse of inhaled sympathomimetic medicines. Using too much can cause dangerous heart effects.
• Cardiovascular effects: Albuterol can raise heart rate and blood pressure and cause ECG (heart rhythm) changes in some people. Use with extra caution if you have heart disease, coronary insufficiency, arrhythmias, or high blood pressure.
• Eye safety: Avoid spraying into eyes. Accidental contact can cause eye pain, blurred vision, and may trigger or worsen narrow-angle glaucoma.
• Urinary retention: Ipratropium may make it harder to urinate. Use cautiously if you have an enlarged prostate or bladder-neck obstruction.
• Low potassium (hypokalemia): Albuterol can temporarily lower blood potassium, which may affect heart rhythm.
• Severe allergic reactions: Hives, swelling, rash, or anaphylaxis can occur — stop the medicine and get emergency care immediately.

Several types of medicines can interact with albuterol and ipratropium inhalation and should be discussed with your prescriber or pharmacist.

• Other anticholinergic medicines (certain drugs for bladder, stomach, or Parkinson's disease) — may add to side effects like dry mouth, constipation, or urinary difficulty.
• Other beta-agonist inhalers (additional albuterol or similar products) — increases risk of cardiovascular side effects.
• Beta-blockers (e.g., metoprolol, atenolol, propranolol) — block the airway-opening effect of albuterol; use with extreme caution in people with reactive airways.
• MAO inhibitors or tricyclic antidepressants (e.g., phenelzine, amitriptyline) — can dangerously amplify albuterol's effects on the heart; avoid within 2 weeks of stopping these drugs.
• Non-potassium-sparing diuretics (loop or thiazide water pills, e.g., furosemide, hydrochlorothiazide) — may worsen low potassium and heart rhythm changes caused by albuterol.

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

• Tell your doctor if you are allergic to atropine, ipratropium, albuterol, or any component of these products — this medicine is contraindicated in those with such allergies.
• Tell your doctor if you have narrow-angle glaucoma — ipratropium may raise eye pressure.
• Tell your doctor if you have an enlarged prostate or bladder problems — ipratropium may worsen urinary retention.
• Tell your doctor if you have heart disease, cardiac arrhythmias, coronary insufficiency, or high blood pressure — albuterol can affect heart rate and rhythm.
• Tell your doctor if you have seizures, diabetes, or an overactive thyroid (hyperthyroidism) — albuterol should be used cautiously in these conditions.
• Pregnancy: There are no well-controlled studies in pregnant women. Animal data showed some concerns with high-dose albuterol. During labor, use only if benefits clearly outweigh risks.
• Breastfeeding: It is not known whether this medicine passes into breast milk in significant amounts; discuss with your doctor.
• Children: Safety and effectiveness of Combivent Respimat in pediatric patients have not been established. COPD does not normally occur in children.
• Older adults: In clinical trials of Combivent Respimat, no overall differences in effectiveness or safety were found in patients 65 and older compared to younger patients, and no dose adjustment is needed based on age alone.

An overdose of this combination would likely be driven by albuterol, since ipratropium is not well absorbed into the bloodstream. Symptoms may include fast heart rate, irregular heartbeat, high or low blood pressure, seizures, tremor, headache, nervousness, nausea, dizziness, and low blood potassium. In severe cases, cardiac arrest is possible.

If you think you or someone else has used too much, stop the medicine and seek emergency medical care right away. Do not try to manage an overdose at home.

At recommended doses, ipratropium bromide does not cause clinically meaningful changes in heart rate or blood pressure, and it does not appear to affect pupil size, vision, or the ability of the lungs to clear mucus. Albuterol, however, can produce measurable cardiovascular effects in some patients — including changes in pulse rate, blood pressure, and heart rhythm tracings — even at recommended doses. These effects are more likely if the recommended dose is exceeded.

Ipratropium's airway-opening effect is mostly local — it acts directly in the lungs rather than through the bloodstream. Only a very small fraction of an inhaled dose is absorbed into the body, and what is absorbed is cleared rapidly by the kidneys. Albuterol is metabolized in the body rather than through the usual breakdown pathways for similar drugs, making it longer-acting; it reaches peak blood levels within about an hour of nebulizer dosing and has a half-life (the time for half the drug to clear the body) of roughly 6–7 hours. A small portion of both drugs is excreted unchanged in the urine.

PROTECT FROM LIGHT. stored in the protective foil pouch until time of use. Store at 20°C to 25°C (68°F and 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) .